Fate Therapeutics Inc (FATE)

[jondoeuk]

AACR abstracts

A novel method to produce clinical scale induced pluripotent stem cell-derived natural killer (iPSC-NK) cells with improved anti-tumor activity for next-generation allogenic cell therapies https://www.abstractsonline.com/pp8/#!/10517/presentation/14665

Targeting hematological malignancies and solid tumors with switchable chimeric antigen receptor-engineered iPSC-derived natural killer cells https://www.abstractsonline.com/pp8/#!/10517/presentation/16686

Development of an iPSC-derived NK cell screening platform for discovery of NK cell optimized Chimeric Antigen Receptors (CARs) for next-generation CAR-NK cell immunotherapies https://www.abstractsonline.com/pp8/#!/10517/presentation/16679

Combined use of human iPSC-derived natural killer cells with macrophages and anti-CD47 blockade to improve killing of acute myeloid leukemia https://www.abstractsonline.com/pp8/#!/10517/presentation/16676